FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

ABSTRACT: This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

DISEASE(S): Ovarian Cancer,Colorectal Cancer,Non Small Cell Lung Cancer,Head And Neck Cancer,Pancreatic Cancer,Gastroesophageal Cancer,Breast Cancer

PROVIDER: 2732221 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR